| __timestamp | Agios Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 302156000 |
| Thursday, January 1, 2015 | 35992000 | 402271000 |
| Friday, January 1, 2016 | 50714000 | 476593000 |
| Sunday, January 1, 2017 | 71124000 | 554336000 |
| Monday, January 1, 2018 | 114145000 | 604353000 |
| Tuesday, January 1, 2019 | 132034000 | 680924000 |
| Wednesday, January 1, 2020 | 149070000 | 737669000 |
| Friday, January 1, 2021 | 121445000 | 759375000 |
| Saturday, January 1, 2022 | 121673000 | 854009000 |
| Sunday, January 1, 2023 | 119903000 | 937300000 |
| Monday, January 1, 2024 | 156784000 | 1009025000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining financial health. Over the past decade, BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc. have demonstrated contrasting approaches to SG&A efficiency. From 2014 to 2023, BioMarin's SG&A expenses surged by approximately 210%, peaking at nearly $937 million in 2023. This reflects their aggressive expansion strategy and investment in administrative capabilities. In contrast, Agios Pharmaceuticals saw a more modest increase of around 530%, reaching about $120 million in the same period. This suggests a more conservative approach, focusing on streamlined operations. The data highlights the strategic choices each company has made in balancing growth with operational efficiency. As the biotech industry continues to evolve, these insights offer valuable lessons in financial management and strategic planning.
Breaking Down SG&A Expenses: Novo Nordisk A/S vs BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Sanofi vs BioMarin Pharmaceutical Inc.
Gilead Sciences, Inc. and Agios Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Bio-Techne Corporation vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
BioMarin Pharmaceutical Inc. or Ionis Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Veracyte, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Bausch Health Companies Inc.
Cost Management Insights: SG&A Expenses for Catalent, Inc. and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Verona Pharma plc or Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? ADMA Biologics, Inc. or Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared